Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial
Open Access
- 30 August 2026
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 32 (11) , 4047-4055
Abstract
Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) therapies include both TTR gene silencers and TTR stabilizers. The role of TTR gene silencers added to background TTR stabilizer therapy is unknown, and the effects of silencer treatment in the absence of stabilizer use are unclear. In the CARDIO-TTRansform study, 1,432 patients ( n = 135 (9.4%) women and n = 1,297 (90.6%) men) with ATTR-CM were randomized (1:1) and treated with the antisense oligonucleotide eplontersen (45 mg every 4 weeks) that targets TTR or with placebo for up to 140 weeks. At baseline, 57% of the patients were taking TTR stabilizers. In the overall study, treatment with eplontersen did not reduce the primary composite endpoint. Here, in a prespecified analysis, we show that the primary endpoint (a composite of cardiovascular mortality and recurrent cardiovascular events) was modified by baseline stabilizer use ( P interaction = 0.017). Benefits were observed in those patients not on stabilizers at baseline (rate ratio (RR) = 0.71, 95% confidence interval (CI) 0.54 to 0.93, P = 0.012), whereas no benefits were observed in those on stabilizers at baseline (RR = 1.14, 95% CI 0.85 to 1.53, P = 0.39). The safety profile of eplontersen was favorable, irrespective of baseline stabilizer use. Treatment with eplontersen versus placebo demonstrated a clinically meaningful benefit among patients not receiving background stabilizers but provided no additional clinical benefit in those on background stabilizer therapy. These findings of a strong treatment effect modification may offer insight for therapeutic decision-making in clinical practice. ClinicalTrials.gov registration: NCT04136171 .Keywords
This publication has 20 references indexed in Scilit:
- Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid CardiomyopathyJACC, 2025
- Exercise Limitations in Amyloid Cardiomyopathy Assessed by Cardiopulmonary Exercise Testing—A Multicentre StudyESC Heart Failure, 2024
- Health-related quality of life is an independent predictor of mortality and hospitalisations in transthyretin amyloid cardiomyopathy: a prospective cohort studyQuality of Life Research, 2024
- Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)Journal of Cardiac Failure, 2024
- Cardiac Amyloidosis Due to Transthyretin ProteinJAMA, 2024
- Eplontersen for Hereditary Transthyretin Amyloidosis With PolyneuropathyJAMA, 2023
- Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosisHeart Failure Reviews, 2022
- Transthyretin Amyloid CardiomyopathyJACC, 2019
- Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2018
- Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseasesStructure, 1997